1st half of 2024: HARTMANN’s positive business performance continues – earnings forecast for current financial year raised

• Organic sales growth of 3.1% leads to sales revenues of EUR 1,195.4 million
• Adjusted EBITDA of EUR 135.9 million, more than EUR 40 million higher than previous year
• Transformation Program makes significant contribution to earnings
• Range of earnings forecast for 2024 increased by EUR 10 million to EUR 220-260 million

Heidenheim, 13 August 2024. Sales and raw material markets remain challenging, but general conditions have stabilized for the first time compared to the previous year. The positive effects of the HARTMANN GROUP's Transformation Program again contributed to an increase in earnings. The Company implemented cost-saving measures in freight and logistics concepts. Product launches in the past two quarters led to increases in sales. In particular, volume increases were achieved in the Wound Care, Incontinence Management and Disinfection divisions.

In the first half of 2024, organic sales growth of 3.1% led to sales revenues of EUR 1,195.4 million. Adjusted EBITDA of EUR 135.9 million was more than EUR 40 million higher than the previous year’s figure.

The Wound Care segment achieved volume growth in the strategic growth area of advanced wound care, particularly in France, the USA and Germany.

The Incontinence Management segment achieved sales growth with incontinence pants, particularly in major European countries and Australia.

The Infection Management segment showed differing developments. In the Risk Prevention division, sales declined due to falling market prices for examination and surgical gloves, as well as personal protective equipment. The Disinfection division saw growth in both surface and hand disinfection, supported by product launches. The Company recorded positive developments in both inpatient and outpatient care. In Germany and Switzerland, market share increased in the pharmacy business.

In the Complementary Group Divisions segment, CMC continued to develop positively. KOB and Kneipp reported declining sales.

HARTMANN will continue to focus on the Transformation Program in 2024. The program is expected to contribute an additional EUR 50 million to earnings in 2024 and further strengthen the Company's competitiveness and resilience.

Although costs for materials and freight are expected to increase in the second half of 2024, the HARTMANN GROUP expects moderate organic sales growth for the 2024 financial year and is increasing its outlook for adjusted EBITDA by EUR 10 million to EUR 220 to 260 million.

The HARTMANN GROUP is one of the leading European providers of professional medical and care products and associated services. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®, Cosmopor®) and Infection Management (e. g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” HARTMANN generated sales of EUR 2.3 billion in the 2023 financial year. Founded in 1818, the Company sells its products and solutions in 130 countries around the world. For the future, the HARTMANN GROUP is currently implementing its strategic Transformation Program with its high-performance, customer-oriented and passionate team.

To learn more about the HARTMANN GROUP, visit www.corporate.hartmann.info.